Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) is not designed as a short-term course. Clinical trials and the medicine's UK licence both frame it as a treatment used alongside long-term lifestyle changes, and stopping early typically leads to weight returning. That said, some people do use it for a defined period, and understanding what the evidence says helps you make an informed choice with a prescriber. Wegovy is a prescription-only medicine; a clinician decides whether it is appropriate for you and for how long.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you've been offered Wegovy, or you're already thinking about it, but you want a fixed endpoint. A wedding in six months. A surgery coming up. A health target you've been given. The idea of an open-ended treatment feels like more commitment than you signed up for. It's a completely reasonable thing to ask about.
The honest answer is that Wegovy works by keeping semaglutide levels steady in your body week after week, gradually suppressing appetite and slowing gastric emptying. Once you stop, those effects reverse. The STEP 1 trial, published in the New England Journal of Medicine, showed participants lost around 15% of body weight on average over 68 weeks at the 2.4 mg maintenance dose. A follow-up study found that one year after stopping, roughly two-thirds of that weight had returned. The body's own appetite signals, suppressed during treatment, reassert themselves.
That is not a reason to avoid Wegovy. It is a reason to understand that a short course tends to produce short-term results. If your goal is a permanent change in your weight, the current clinical consensus is that treatment needs to continue for results to persist, or be paired with very robust lifestyle changes that can hold the ground once the medicine stops. The Wegovy overview on our treatment page covers the full picture of how it works and who it suits.
There is no minimum treatment period written into the Wegovy licence. You could, in theory, stop after four weeks. But the UK licence frames the medicine as part of a long-term weight management programme, not a sprint. NICE's appraisal of semaglutide, TA875, recommends it for a maximum of two years, within a specialist weight management service, for adults with a BMI of 35 or above and at least one weight-related health condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Critically, NICE also says treatment should be reviewed and stopped if less than 5% weight loss is achieved after six months on the maintenance dose. The upper ceiling is two years; there is no official minimum short course.
This matters for short-term use because it means: a prescriber may legitimately support a time-limited course in specific clinical circumstances. Pre-operative weight loss is one example, where reducing BMI before surgery carries genuine medical benefit and a clear endpoint. Someone who cannot tolerate the medicine, or whose circumstances change, may stop earlier than planned. None of this is the same as planning a three-month course because it seems more manageable. If you are wondering whether you can take Wegovy for a short time, the right conversation is with a prescriber who knows your full health history.
It is also worth knowing that long-term Wegovy use has its own questions, there is a companion page that explores what continuing treatment beyond a year actually looks like in practice.
Even if you decide on a defined period, the way semaglutide is prescribed shapes what is realistic. Wegovy starts at 0.25 mg, stepping up roughly every four weeks through 0.5 mg, 1.0 mg, 1.7 mg to the 2.4 mg maintenance dose. That is a minimum of roughly four to five months before you reach the dose at which the most significant results occur. A three-month course would mean spending the entire time in the dose-escalation phase, a period that exists mainly to reduce gastrointestinal side effects, not to produce peak therapeutic effect.
In practice, this means a genuinely 'short' course is often either a course that ends early for medical or personal reasons, or a planned time-limited treatment at full dose for someone who has already titrated up. If you've been on Wegovy before and are restarting, your prescriber will assess whether you need to re-titrate. If you're starting fresh, the five-month escalation ladder is part of the deal. The detail on what short-term use actually involves is worth reading before you decide.
One thing that catches people out: the cost mounts up even before you reach full dose. Reviewing how Wegovy is priced across the titration schedule can help you plan properly if you have a defined budget or time frame in mind.
Prescribers don't have a set objection to time-limited treatment. What they want is clarity about your reasons and confidence that the plan is safe and proportionate. A GP or independent prescriber reviewing a request for short-term semaglutide use will typically think about: your starting BMI and health conditions; whether there is a specific medical reason for the time limit; what your weight management plan looks like once the medicine stops; and whether the titration schedule can realistically be completed within your proposed window.
They will also check whether you meet the licensed eligibility criteria, BMI of 30 or above, or 27 to 29.9 with a relevant weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. BMI alone never settles the decision. The full clinical picture, including any medicines you take and any conditions that would make Wegovy unsuitable, goes into the assessment. Some people also notice unexpected changes during treatment, and if you have been experiencing spotting on Wegovy, that is something to raise with your prescriber as part of the wider assessment. If you're not sure whether you'd qualify, checking your BMI using the NHS BMI calculator is a useful first step, but it's the starting point rather than the answer.
Our prescribers at nume work through exactly this kind of assessment for every new patient. If short-term semaglutide use makes clinical sense for your situation, that will come out of the consultation. If the evidence points toward a longer course being more appropriate, they'll explain why. You can start your free consultation at any time, assessments are reviewed by a real prescriber the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.